Barbara Belletti

Aviano, 33081, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 68 publications

Time-varying hazard rates reveal patterns of progression in HR+/HER2- metastatic breast cancer: Towards risk-adapted monitoring.

Time-varying hazard rates reveal patterns of progression in HR+/HER2- metastatic breast cancer: Towards risk-adapted monitoring.

Journal: Translational oncology
Published: July 06, 2026

Targeting CDK4/6 in Combination with Phage-Based Anti-HER2 Vaccination Overcomes Immune Evasion and Enhances the Anticancer Response in Breast Cancer.

Targeting CDK4/6 in Combination with Phage-Based Anti-HER2 Vaccination Overcomes Immune Evasion and Enhances the Anticancer Response in Breast Cancer.

Journal: Pharmaceutics
Published: June 04, 2026

Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma.

Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: April 29, 2026

CDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism.

CDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism.

Journal: Signal transduction and targeted therapy
Published: January 20, 2026

Distinct 2-phenylimidazo[1,2-a]pyridine derivatives that inhibit breast cancer cell proliferation identified as AHR ligands.

Distinct 2-phenylimidazo[1,2-a]pyridine derivatives that inhibit breast cancer cell proliferation identified as AHR ligands.

Journal: iScience
Published: October 22, 2025

Baseline systemic inflammatory indices predict late radiation-induced fibrosis and toxicity in patients with early breast cancer.

Baseline systemic inflammatory indices predict late radiation-induced fibrosis and toxicity in patients with early breast cancer.

Journal: Breast (Edinburgh, Scotland)
Published: October 07, 2025

Epigenetic and fragment-based profiling across CDK4/6 inhibitors in first-line HR+/HER2- metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 study.

Epigenetic and fragment-based profiling across CDK4/6 inhibitors in first-line HR+/HER2- metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 study.

Journal: Breast (Edinburgh, Scotland)
Published: June 24, 2025

ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer.

ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer.

Journal: Cancer research
Published: April 13, 2025

Impact of opioid-free general anesthesia with locoregional blocks during breast cancer surgery on systemic inflammatory response: results from a randomized controlled trial.

Impact of opioid-free general anesthesia with locoregional blocks during breast cancer surgery on systemic inflammatory response: results from a randomized controlled trial.

Journal: Regional anesthesia and pain medicine
Published: February 05, 2025

Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics.

Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics.

Journal: Translational oncology
Published: December 15, 2024

USP1 deubiquitinates PARP1 to regulate its trapping and PARylation activity.

USP1 deubiquitinates PARP1 to regulate its trapping and PARylation activity.

Journal: Science advances
Published: November 13, 2024

miR-1297 is frequently downmodulated in flat epithelial atypia of the breast and promotes mammary neoplastic transformation via EphrinA2 regulation.

miR-1297 is frequently downmodulated in flat epithelial atypia of the breast and promotes mammary neoplastic transformation via EphrinA2 regulation.

Journal: Journal of experimental & clinical cancer research : CR
Published: October 31, 2024
Showing 1-12 of 68

Last Updated: 09/26/2026